Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment
Frank Xiaoqing Liu,1 Edward A Witt,2 Scot Ebbinghaus,1 Grace DiBonaventura Beyer,2 Reshma Shinde,1 Enrique Basurto,2 Richard W Joseph3 1Merck & Co., Inc., Kenilworth, NJ, USA; 2Kantar Health, New York, NY, USA; 3Mayo Clinic, Jacksonville, FL, USA Purpose: To examine and compare patient and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-08-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patient-and-oncologist-preferences-for-attributes-of-treatments-in-adv-peer-reviewed-article-PPA |
| _version_ | 1819136530632933376 |
|---|---|
| author | Liu FX Witt EA Ebbinghaus S DiBonaventura Beyer G Shinde R Basurto E Joseph RW |
| author_facet | Liu FX Witt EA Ebbinghaus S DiBonaventura Beyer G Shinde R Basurto E Joseph RW |
| author_sort | Liu FX |
| collection | DOAJ |
| description | Frank Xiaoqing Liu,1 Edward A Witt,2 Scot Ebbinghaus,1 Grace DiBonaventura Beyer,2 Reshma Shinde,1 Enrique Basurto,2 Richard W Joseph3 1Merck & Co., Inc., Kenilworth, NJ, USA; 2Kantar Health, New York, NY, USA; 3Mayo Clinic, Jacksonville, FL, USA Purpose: To examine and compare patient and oncologist preferences for advanced melanoma treatment attributes and to document their trade-offs for benefits with risks. Materials and methods: A discrete choice experiment (DCE) was conducted among advanced melanoma patients and oncologists. Qualitative pilot testing was used to inform the DCE design. A series of scenarios asked stakeholders to choose between two hypothetical medications, each with seven attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (MDT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3–4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to determine patients’ and oncologists’ choice-based preferences, analysis of variance models were used to estimate the relative importance of attributes, and independent t-tests were used to compare relative importance estimates between stakeholders. Results: In total, 200 patients and 226 oncologists completed the study. OS was most important to patients (33%), followed by AEs (29%) and ORR (25%). For oncologists, AEs were most important (49%), followed by OS (34%) and ORR (12%). An improvement from 55% to 75% in 1-year OS was valued similar in magnitude to a 23% decrease (from 55% to 32%) in likelihood of AEs for oncologists.Conclusion: Patients valued OS, AEs, and ORR sequentially as the most important attributes in making a treatment decision, whereas oncologists valued AEs most, followed by OS and ORR. In comparison, patients differed significantly from oncologists on the importance of ORR, AEs, and PFS, but were consistent in OS and the rest of attributes. Keywords: unresectable, metastatic melanoma, systemic therapy, discrete choice experiment |
| first_indexed | 2024-12-22T10:36:27Z |
| format | Article |
| id | doaj.art-dba4aef47bbf4953baf9cbc08a85e5a0 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-22T10:36:27Z |
| publishDate | 2017-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-dba4aef47bbf4953baf9cbc08a85e5a02022-12-21T18:29:11ZengDove Medical PressPatient Preference and Adherence1177-889X2017-08-01Volume 111389139934243Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experimentLiu FXWitt EAEbbinghaus SDiBonaventura Beyer GShinde RBasurto EJoseph RWFrank Xiaoqing Liu,1 Edward A Witt,2 Scot Ebbinghaus,1 Grace DiBonaventura Beyer,2 Reshma Shinde,1 Enrique Basurto,2 Richard W Joseph3 1Merck & Co., Inc., Kenilworth, NJ, USA; 2Kantar Health, New York, NY, USA; 3Mayo Clinic, Jacksonville, FL, USA Purpose: To examine and compare patient and oncologist preferences for advanced melanoma treatment attributes and to document their trade-offs for benefits with risks. Materials and methods: A discrete choice experiment (DCE) was conducted among advanced melanoma patients and oncologists. Qualitative pilot testing was used to inform the DCE design. A series of scenarios asked stakeholders to choose between two hypothetical medications, each with seven attributes: mode of administration (MoA), dosing schedule (DS), median duration of therapy (MDT), objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and grade 3–4 adverse events (AEs). Hierarchical Bayesian logistic regression models were used to determine patients’ and oncologists’ choice-based preferences, analysis of variance models were used to estimate the relative importance of attributes, and independent t-tests were used to compare relative importance estimates between stakeholders. Results: In total, 200 patients and 226 oncologists completed the study. OS was most important to patients (33%), followed by AEs (29%) and ORR (25%). For oncologists, AEs were most important (49%), followed by OS (34%) and ORR (12%). An improvement from 55% to 75% in 1-year OS was valued similar in magnitude to a 23% decrease (from 55% to 32%) in likelihood of AEs for oncologists.Conclusion: Patients valued OS, AEs, and ORR sequentially as the most important attributes in making a treatment decision, whereas oncologists valued AEs most, followed by OS and ORR. In comparison, patients differed significantly from oncologists on the importance of ORR, AEs, and PFS, but were consistent in OS and the rest of attributes. Keywords: unresectable, metastatic melanoma, systemic therapy, discrete choice experiment https://www.dovepress.com/patient-and-oncologist-preferences-for-attributes-of-treatments-in-adv-peer-reviewed-article-PPApatient preferenceoncologist preferencetreatment attributesadvanced melanomaoncologydiscrete choice experiment |
| spellingShingle | Liu FX Witt EA Ebbinghaus S DiBonaventura Beyer G Shinde R Basurto E Joseph RW Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment Patient Preference and Adherence patient preference oncologist preference treatment attributes advanced melanoma oncology discrete choice experiment |
| title | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
| title_full | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
| title_fullStr | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
| title_full_unstemmed | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
| title_short | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment |
| title_sort | patient and oncologist preferences for attributes of treatments in advanced melanoma a discrete choice experiment |
| topic | patient preference oncologist preference treatment attributes advanced melanoma oncology discrete choice experiment |
| url | https://www.dovepress.com/patient-and-oncologist-preferences-for-attributes-of-treatments-in-adv-peer-reviewed-article-PPA |
| work_keys_str_mv | AT liufx patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT wittea patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT ebbinghauss patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT dibonaventurabeyerg patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT shinder patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT basurtoe patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment AT josephrw patientandoncologistpreferencesforattributesoftreatmentsinadvancedmelanomaadiscretechoiceexperiment |